PDE7A and breast carcinoma: IBMX (500 μM), dipyridamole (100 μM), milrinone (10 μM), piclamilast (1 μM), rolipram (10 μM), the PDE7 inhibitor spiroquinazolinone (1 μM) and the PDE8 inhibitor PF-04957325 (1 μM) significantly attenuated the migration of MDA-MB-231 breast cancer cells in transwell and/or wound healing assays [51].